As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated risk of recurrence following surgery. The decision authorizes the use of pembrolizumab (Keytruda), including its subcutaneous formulation (Keytruda Qlex), in combination with belzutifan (Welireg), marking a notable advance in earlier-stage disease management.
Expanded Treatment Option in Earlier-Stage Disease
This approval applies to patients who have undergone nephrectomy, with or without removal of metastatic lesions, and are classified as having intermediate-high or high recurrence risk. Importantly, it represents the first time belzutifan—previously used in more advanced settings—has been cleared for earlier-stage ccRCC. It also introduces the first approved regimen combining a programmed death receptor-1 (PD-1) inhibitor with a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.
Evidence From Phase III Trial
Regulatory clearance was supported by findings from the Phase III LITESPARK-022 study, which enrolled 1,841 patients. The combination regimen demonstrated a statistically significant improvement in disease-free survival (DFS), the primary endpoint of the trial.
Patients receiving pembrolizumab plus belzutifan experienced a 28% reduction in the risk of recurrence, metastasis, or death compared with those treated with pembrolizumab and placebo. At 24 months, an estimated 81% of patients in the combination arm remained disease-free, versus 74% in the comparator group. Median DFS had not yet been reached in either arm at the time of analysis, and overall survival data remain immature.
Approval of the subcutaneous Keytruda Qlex formulation was supported by bridging data demonstrating comparable pharmacokinetics, safety, and efficacy to intravenous pembrolizumab.
Safety Profile and Monitoring Considerations
As with many oncology therapies, the regimen carries important safety considerations. Belzutifan includes a boxed warning related to embryo-fetal toxicity and requires confirmation of pregnancy status prior to treatment initiation. Patients should be advised that hormonal contraceptives may be less effective, necessitating alternative methods.
Additionally, belzutifan has been associated with significant anemia and hypoxia, underscoring the need for ongoing monitoring and potential intervention. Pembrolizumab formulations, both intravenous and subcutaneous, are linked to immune-mediated adverse reactions, including organ inflammation, infusion-related reactions, and potential transplant complications.
Keytruda Qlex is contraindicated in individuals with known hypersensitivity to its enzymatic component or related agents.
Clinical Perspective
According to Merck leadership, the approval reflects continued efforts to improve outcomes for patients facing a high likelihood of disease recurrence after surgery. Enhancing disease-free survival is particularly meaningful in earlier-stage cancer, where delaying or preventing relapse can significantly influence long-term prognosis and quality of life.
Broader Context
Beyond clinical developments, Merck has also been investing in innovation across technology and research. In April 2026, the company announced a strategic collaboration with Google Cloud, with plans to invest up to $1 billion in artificial intelligence–driven enterprise transformation, highlighting its broader commitment to advancing oncology care and research infrastructure.
Outlook
The introduction of pembrolizumab plus belzutifan in the adjuvant setting signals a shift toward more targeted, combination-based approaches earlier in the treatment continuum for ccRCC. As longer-term survival data mature, further insights will help define the full clinical benefit of this regimen in reducing recurrence and improving patient outcomes.
